Cantor Fitzgerald Boosts Endo International (NASDAQ:ENDP) Price Target to $18.00

Share on StockTwits

Endo International (NASDAQ:ENDP) (TSE:ENL) had its target price hoisted by equities researchers at Cantor Fitzgerald from $12.00 to $18.00 in a research note issued on Friday, October 19th, The Fly reports. The brokerage presently has a “neutral” rating on the stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 33.43% from the company’s current price.

Other equities research analysts also recently issued research reports about the stock. Royal Bank of Canada upgraded shares of Endo International from a “sector perform” rating to an “outperform” rating and set a $26.00 target price for the company in a research report on Monday, August 13th. Zacks Investment Research upgraded shares of Endo International from a “hold” rating to a “buy” rating and set a $18.00 target price for the company in a research report on Monday, September 24th. Goldman Sachs Group upgraded shares of Endo International from a “sell” rating to a “neutral” rating and increased their target price for the stock from $14.00 to $15.00 in a research report on Tuesday, September 11th. TheStreet upgraded shares of Endo International from a “d” rating to a “c-” rating in a research report on Monday, August 20th. Finally, BidaskClub downgraded shares of Endo International from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 8th. One analyst has rated the stock with a sell rating, fourteen have given a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $14.97.

Shares of NASDAQ:ENDP traded up $0.30 during mid-day trading on Friday, hitting $13.49. The stock had a trading volume of 6,440,068 shares, compared to its average volume of 4,723,015. The company has a market cap of $3.59 billion, a PE ratio of 3.51, a price-to-earnings-growth ratio of 1.54 and a beta of 0.65. Endo International has a 12-month low of $5.27 and a 12-month high of $18.50.

Endo International (NASDAQ:ENDP) (TSE:ENL) last issued its quarterly earnings results on Thursday, November 8th. The company reported $0.71 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.59 by $0.12. The business had revenue of $745.00 million during the quarter, compared to the consensus estimate of $694.93 million. Endo International had a negative net margin of 34.72% and a positive return on equity of 237.45%. The firm’s quarterly revenue was down 5.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.91 EPS. As a group, sell-side analysts predict that Endo International will post 2.68 EPS for the current year.

In other Endo International news, Director Roger H. Kimmel sold 26,074 shares of the firm’s stock in a transaction on Tuesday, August 14th. The shares were sold at an average price of $15.90, for a total value of $414,576.60. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Company insiders own 0.80% of the company’s stock.

Several institutional investors have recently modified their holdings of ENDP. Xact Kapitalforvaltning AB boosted its position in shares of Endo International by 44.5% during the 1st quarter. Xact Kapitalforvaltning AB now owns 29,215 shares of the company’s stock valued at $174,000 after acquiring an additional 9,000 shares in the last quarter. James Investment Research Inc. boosted its position in shares of Endo International by 594.9% during the 3rd quarter. James Investment Research Inc. now owns 10,945 shares of the company’s stock valued at $184,000 after acquiring an additional 9,370 shares in the last quarter. Harvest Fund Management Co. Ltd acquired a new stake in shares of Endo International during the 3rd quarter valued at about $223,000. Cim Investment Mangement Inc. acquired a new stake in shares of Endo International during the 3rd quarter valued at about $262,000. Finally, First Hawaiian Bank acquired a new stake in shares of Endo International during the 3rd quarter valued at about $358,000. Institutional investors and hedge funds own 98.43% of the company’s stock.

Endo International Company Profile

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.

Featured Story: What is the 52-week high/low?

The Fly

Analyst Recommendations for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.